Tolosa E, Valldeoriola F
Service of Neurology, Hospital Clinic i Provincial, Barcelona, Spain.
Clin Neuropharmacol. 1994;17 Suppl 2:S19-31.
Most patients with Parkinson's disease who undergo levodopa therapy eventually develop fluctuations in the diurnal control of their symptoms. These fluctuations, when mild, consist mostly of the "wearing-off" effect--the re-emergence of symptoms several hours after the ingestion of each dose of levodopa. In some patients, "wearing-off" in the daytime is preceded by, or associated with, the development of nocturnal and early morning akinesia. Some patients at this stage also have mild (mostly peak dose or square-wave) choreoathetoid dyskinesias. In patients with "wearing-off," "on" periods tend to occur when plasma levels of levodopa are high; nocturnal and early morning akinesia and diurnal "off" periods tend to occur at times when plasma levodopa levels are low, reflecting insufficient concentrations of dopamine in the striatum. Treatment strategies in patients with mid-stage parkinsonism and mild fluctuations are primarily directed toward enhancing dopaminergic transmission in the striatum. This is achieved by increasing the supply of levodopa to the brain or by administering drugs that either prolong the effect of synaptic dopamine from levodopa, or activate postsynaptic dopamine receptors. This presentation will discuss the advantages and possible drawbacks of these different strategies, which include the use of controlled-release levodopa preparations, deprenyl, and the new monoamine oxidase (MAO)-B inhibitors, catechol-O-methyl transferase (COMT) inhibitors, and the various "direct" dopamine agonists.
大多数接受左旋多巴治疗的帕金森病患者最终会出现症状日间控制的波动。这些波动在轻度时,主要表现为“剂末现象”——每次服用左旋多巴数小时后症状重新出现。在一些患者中,日间“剂末现象”之前或与之相关的是夜间和清晨运动不能的出现。在这个阶段,一些患者还会出现轻度(主要是峰剂量或方波)舞蹈手足徐动样运动障碍。在有“剂末现象”的患者中,“开”期往往出现在左旋多巴血浆水平较高时;夜间和清晨运动不能以及日间“关”期往往出现在血浆左旋多巴水平较低时,这反映了纹状体内多巴胺浓度不足。中期帕金森病且波动较轻患者的治疗策略主要是增强纹状体内的多巴胺能传递。这可以通过增加左旋多巴向脑内的供应,或通过给予能延长左旋多巴突触多巴胺作用或激活突触后多巴胺受体的药物来实现。本报告将讨论这些不同策略的优点和可能的缺点,这些策略包括使用控释左旋多巴制剂、司来吉兰以及新型单胺氧化酶(MAO)-B抑制剂、儿茶酚-O-甲基转移酶(COMT)抑制剂和各种“直接”多巴胺激动剂。